Guidelines of the Belgian Hematological Society for newly diagnosed and relapsed follicular lymphoma 2012

peer reviewed ; Follicular lymphoma is an indolent lymphoma that has occurred more frequently over the last decades. In this article we present an overview of the diagnosis and initial work-up, prognostic scoring system and choice of therapy. For limited stage disease radiotherapy is the treatment of choice, and may have a curative potential. For advanced stages treatment should be initiated upon certain criteria, and is essentially based on immunochemotherapy, rituximab plus chemotherapy. The choice of chemotherapy depends on age, frailty, and specific toxicities of chemotherapy. Maintenance... Mehr ...

Verfasser: Debussche, S.
Van Hoof, A.
Sonet, Anne
Bonnet, Christophe
Janssens, A.
Verhoef, Grégor
Dierickx, D.
De Wilde, V.
Bron, Dominique
Schroyens, W.
Van Den Neste, Eric
Offner, Fritz
Dokumenttyp: journal article
Erscheinungsdatum: 2012
Verlag/Hrsg.: Ariez Medical Publishing
Schlagwörter: follicular lymphoma / guidelines / Human health sciences / Hematology / Sciences de la santé humaine / Hématologie
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-28888522
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://orbi.uliege.be/handle/2268/144299

peer reviewed ; Follicular lymphoma is an indolent lymphoma that has occurred more frequently over the last decades. In this article we present an overview of the diagnosis and initial work-up, prognostic scoring system and choice of therapy. For limited stage disease radiotherapy is the treatment of choice, and may have a curative potential. For advanced stages treatment should be initiated upon certain criteria, and is essentially based on immunochemotherapy, rituximab plus chemotherapy. The choice of chemotherapy depends on age, frailty, and specific toxicities of chemotherapy. Maintenance therapy with rituximab after induction has become standard practice. Since virtually all patients relapse eventually, an overview of the treatment in the relapsed setting is given. The treatment is then again based on immunochemotherapy but there is also a place for radio-immunotherapy, or immunotherapy alone. For young patients, high dose chemotherapy with autologous stem cell rescue should be considered. A brief overview on novel agents, and agents that are in the pipeline, is given. We conclude with some recommendations for follow-up.